Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks

Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7

Standard of care surgical resection of tumor on Day 10-28